Episode

Episode 199 - Miles Gerson - Partner at SV Health Investors and Co-Lead of The Dementia Discovery Fund

Podcast
The BioHub - by Avetix
Published
Jul 13, 2026
Duration seconds
1681
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-199---Miles-Gerson---Partner-at-SV-Health-Investors-and-Co-Lead-of-The-Dementia-Discovery-Fund-e3m0ret
Audio
https://anchor.fm/s/f0076084/podcast/play/122760093/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-13%2F427857311-44100-2-70cd55ed9b18b.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-199-miles-gerson-partner-at-sv-health-investors-and-co-lead-of-the-dementia-discovery-fund
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-199-miles-gerson-partner-at-sv-health-investors-and-co-lead-of-the-dementia-discovery-fund.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-199-miles-gerson-partner-at-sv-health-investors-and-co-lead-of-the-dementia-discovery-fund/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-199-miles-gerson-partner-at-sv-health-investors-and-co-lead-of-the-dementia-discovery-fund.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of The BioHub Podcast, Ben sits down with Miles Gerson, Partner at SV Health Investors and Co-Lead of the Dementia Discovery Fund. Miles shares his perspective on investing in neuroscience, building companies around emerging biology and identifying approaches with the potential to change the treatment landscape in dementia and neurodegenerative disease. The conversation explores how the Dementia Discovery Fund assesses scientific risk, what makes a neuroscience company investable, where the strongest opportunities are emerging, and how investors can help translate promising research into viable therapeutic companies. Miles also discusses the evolution of dementia drug development, the role of company creation and what the next generation of successful neuroscience businesses will need to get right.